Apr 2022

Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial

Ostadal P, Steg PG, Poulouin Y, et al.

First published: April 1, 2022  DOI: 10.1016/S2213-8587(22)00043-2